Welcome to STN International! Enter x:x

LOGINID:sssptaul25txc

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Feb 24	PCTGEN now available on STN
NEWS 4	Feb 24	TEMA now available on STN
NEWS 5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 6	Feb 26	PCTFULL now contains images
NEWS 7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8	Mar 24	PATDPAFULL now available on STN
NEWS 9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 10	Apr 11	Display formats in DGENE enhanced
NEWS 11	Apr 14	MEDLINE Reload
NEWS 12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 13	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15	Apr 28	RDISCLOSURE now available on STN
NEWS 16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19	May 19	Simultaneous left and right truncation added to WSCA
NEWS 20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 22	Jun 06	PASCAL enhanced with additional data
NEWS 23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS 24	Jun 25	HSDB has been reloaded
NEWS 25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS 26	Jul 21	Identification of STN records implemented
NEWS 27	Jul 21	Polymer class term count added to REGISTRY
NEWS 28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:12:40 ON 29 JUL 2003

=> file medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'ADISCTI' ENTERED AT 12:12:54 ON 29 JUL 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:12:54 ON 29 JUL 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:12:54 ON 29 JUL 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 12:12:54 ON 29 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHNO' ENTERED AT 12:12:54 ON 29 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'CAPLUS' ENTERED AT 12:12:54 ON 29 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEN' ENTERED AT 12:12:54 ON 29 JUL 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 12:12:54 ON 29 JUL 2003
COPYRIGHT (C) 2003 DERWENT INFORMATION LTD

FILE 'DRUGB' ENTERED AT 12:12:54 ON 29 JUL 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGLAUNCH' ENTERED AT 12:12:54 ON 29 JUL 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 12:12:54 ON 29 JUL 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 12:12:54 ON 29 JUL 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 12:12:54 ON 29 JUL 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBAL' ENTERED AT 12:12:54 ON 29 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'ESBIOBASE' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'IFIPAT' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'IPA' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'JICST-EPLUS' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'KOSMET' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'LIFESCI' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'MEDICONF' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'MEDLINE' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'NAPRALERT' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'NLDB' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'NUTRACEUT' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'PASCAL' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'PCTGEN' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'PHARMAML' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'PHIC' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'PHIN' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'SCISEARCH' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'TOXCENTER' ENTERED AT 12:12:54 ON 29 JUL 2003

FILE 'USPATFULL' ENTERED AT 12:12:54 ON 29 JUL 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:12:54 ON 29 JUL 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s obesity and dihydropyrimidin?
L1 51 OBESITY AND DIHYDROPYRIMIDIN?

=> s l1 and pd<1999
4 FILES SEARCHED...
'1999' NOT A VALID FIELD CODE
9 FILES SEARCHED...
'1999' NOT A VALID FIELD CODE
'1999' NOT A VALID FIELD CODE
16 FILES SEARCHED...
'1999' NOT A VALID FIELD CODE
22 FILES SEARCHED...
'1999' NOT A VALID FIELD CODE
'1999' NOT A VALID FIELD CODE
'1999' NOT A VALID FIELD CODE
26 FILES SEARCHED...
'1999' NOT A VALID FIELD CODE
'1999' NOT A VALID FIELD CODE
34 FILES SEARCHED...
L2 5 L1 AND PD<1999

=> d l2 1-5 bib, ab, kwic

L2 ANSWER 1 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. on STN
AN 76078116 EMBASE
DN 1976078116
TI ['Minvitin' as dietary therapy of **obesity**].
LA MINVITINE, TRAITEMENT DIETETIQUE DE L'OBESITE.
AU Dufrasne M.; Masson J.M.
CS Univ. Liege, Belgium
SO Ars Medici Revue Internationale de Therapie Pratique, (**1975**)
30/6 (1023-1033).
CODEN: AMNVCC
DT Journal
FS 037 Drug Literature Index
006 Internal Medicine
LA French
TI ['Minvitin' as dietary therapy of **obesity**].
LA MINVITINE, TRAITEMENT DIETETIQUE DE L'OBESITE.
SO Ars Medici Revue Internationale de Therapie Pratique, (**1975**)
30/6 (1023-1033).
CODEN: AMNVCC
CT Medical Descriptors:
*anxiety
*body weight
*constipation
*diet
*feeding behavior
***obesity**
*drug therapy
therapy
oral drug administration
***dihydropyrimidinase**
RN (**dihydropyrimidinase**) 9030-74-4

L2 ANSWER 2 OF 5 IFIPAT COPYRIGHT 2003 IFI on STN

AN 2111786 IFIPAT;IFIUDB;IFICDB
TI PYRAZOLOPYRIDINE COMPOUND AND PROCESSES FOR PREPARATION THEREOF
INF Akahane, Atsushi, Hyogo, JP
Katayama, Hirohito, Nishinomiya, JP
Mitsunaga, Takafumi, Ashiya, JP
Shiokawa, Youichi, Ibaraki, JP
IN Akahane Atsushi (JP); Katayama Hirohito (JP); Mitsunaga Takafumi (JP); Shiokawa Youichi (JP)
PAF Fujisawa Pharmaceutical Co, Ltd, Osaka, JP
PA Fujisawa Pharmaceutical Co Ltd JP (32600)
EXNAM Lee, Mary C
EXNAM Dentz, Bernard I
AG Oblon, Spivak, McClelland, Maier & Neustadt
PI US 4985444 19910115 (CITED IN 005 LATER PATENTS)
AI US 1990-466929 19900118
XPD 18 Jan 2010
PRAI GB 1989-1423 19890123
FI US 4985444 19910115
DT UTILITY
FS CHEMICAL
GRANTED
MRN 005496 MFN: 0161
CLMN 16
AB The invention relates to pyrazolopyridine compounds for the treatment of melancholia, heart failure, hypertension, renal insufficiency, edema, **obesity**, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, myocardiac infection, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack or angina pectoris, said compounds being of the formula

D R A W I N G

wherein R1 is aryl, and R2 is unsaturated heterocyclic group which contains at least one heteroatom selected from the group consisting of N, O and S, which may have one or more suitable substituent(s), or a pharmaceutically acceptable salt thereof.

PI US 4985444 19910115 (CITED IN 005 LATER PATENTS)
AB The invention relates to pyrazolopyridine compounds for the treatment of melancholia, heart failure, hypertension, renal insufficiency, edema, **obesity**, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, myocardiac infection, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient. . .

ACLM 3. A compound of claim 2, wherein R1 is phenyl, and R2 is pyridazinyl, dihydropyridazinyl, tetrahydropyridazinyl, pyrimidinyl, **dihydropyrimidinyl**, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrazolyl or imidazothiadiazolyl, each of which may have one or more suitable substituent(s) selected from a group. . .
4. A compound of claim 3, wherein R2 is pyridazinyl, dihydropyridazinyl, tetrahydropyridazinyl, pyrimidinyl, **dihydropyrimidinyl**, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrazolyl or imidazothiadiazolyl, each of which may have 1 to 4 suitable substituent(s) selected from a group. . .
5. A compound of claim 4, wherein R2 is pyridazinyl, dihydropyridazinyl, tetrahydropyridazinyl, pyrimidinyl, **dihydropyrimidinyl**, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrazolyl or imidazothiadiazolyl, each of which may have 1 to 4 suitable substituent(s) selected from a group. . .
. . . pyrimidinyl which may have 1 suitable substituent selected from a group consisting of lower alkyl, amino, halogen and lower alkoxy; **dihydropyrimidinyl** which may have 1 or 2 suitable substituent(s)

selected from a group consisting of lower alkoxycarbonyl(lower)alkyl and oxo; pyridyl which. . .
15. A method for the treatment of melancholia, heart failure, hypertension, renal insufficiency, edema, **obesity**, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppresion, diabetes, myocardial infarction, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient. . .

L2 ANSWER 3 OF 5 USPATFULL on STN
AN 1998:75675 USPATFULL
TI Pyrazolopyridine adenosine antagonists
IN Akahane, Atsushi, Hyogo, Japan
Nishimura, Shintaro, Osaka, Japan
Itani, Hiromichi, Hyogo, Japan
Durkin, Kieran P. M., Folsom, CA, United States
PA Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)
PI US 5773530 19980630 <--
WO 9518128 19950706 <--
AI US 1996-663119 19960913 (8)
WO 1994-JP2230 19941226
19960913 PCT 371 date
19960913 PCT 102(e) date
PRAI GB 1993-26524 19931229
GB 1994-4323 19940304
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Coleman, Brenda
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4147
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel pyrazolopyridine compound of the following formula: ##STR1## wherein R.sup.1 is aryl, and

R.sup.2 is cyclo(lower)alkyl which may have one or more suitable substituent(s), etc; and a pharmaceutically acceptable salt thereof, which is useful as a medicament; the processes for the preparation of said pyrazolopyridine compound or a salt thereof; a pharmaceutical composition comprising said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof; etc.
PI US 5773530 19980630 <--
WO 9518128 19950706 <--
SUMM . . . edema, nephrotic edema, hepatic edema, idiopathic edema, drug edema, acute angioneurotic edema, hereditary angioneurotic edema, carcinomatous ascites, gestational edema, etc); **obesity**, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer such as peptic ulcer (e.g. gastric ulcer, duodenal ulcer,. . .
SUMM . . . or more suitable substituent(s)" may include azepinyl (e.g. 1H-azepinyl, etc) pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl and its N-oxide, dihydropyridyl, pyrimidinyl, **dihydropyrimidinyl** (e.g. 1,2-**dihydropyrimidinyl**, etc), tetrahydropyrimidinyl (e.g. 1,2,3,4-tetrahydropyrimidinyl, etc), pyrazinyl, pyridazinyl, triazolyl (e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc), tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl) and the like;

L2 ANSWER 4 OF 5 USPATFULL on STN
AN 92:84872 USPATFULL

TI Method of treatment using pyrazolopyridine compound
IN Shiokawa, Youichi, Ibaraki, Japan
Akahane, Atsushi, Kawabe, Japan
Katayama, Hirohito, Nishinomiya, Japan
Mitsunaga, Takafumi, Ashiya, Japan
PA Fujisawa Pharmaceutical Company, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 5155114 19921013 <--
AI US 1991-715460 19910614 (7)
DCD 20080115
RLI Continuation-in-part of Ser. No. US 1990-626009, filed on 18 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-466929, filed on 12 Dec 1990, now patented, Pat. No. US 4985444, issued on 15 Jan 1991
PRAI GB 1989-1423 19890123
DT Utility
FS Granted
EXNAM Primary Examiner: Dentz, Bernard
LREP Oblon, Spivak, McClelland, Maier & Neustadt
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2525
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method for the prevention and/or treatment of renal toxicity, nephrosis or nephritis, which comprises administering a pyrazolopyridine compound of the formula: ##STR1## wherein R.sup.1 is aryl, and

R.sup.2 is unsaturated heterocyclic group which contains at least one heteroatom selected from the group consisting of N, O and S, which may have one or more suitable substituent(s), or a pharmaceutically acceptable salt thereof to a human being or an animal.

PI US 5155114 19921013 <--

SUMM . . . edema, nephrotic edema, hepatic edema, idiopathic edema, drug edema, acute angioneurotic edema, hereditary angioneurotic edema, carcinomatous ascites, gestational edema, etc.), **obesity**, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppresion, diabetes, ulcer such as peptic ulcer (e.g. gastic ulcer, duodenal ulcer,. . .

SUMM . . . example, azepinyl (e.g. 1H-azepinyl, etc.) pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl (e.g. 1,2-dihydropyridyl, 1,4-dihydropyridyl, etc.), tetrahydropyridyl (e.g. 1,2,3,6-tetrahydropyridyl, etc.) pyrimidinyl, **dihydropyrimidinyl** (e.g. 1,2-**dihydropyrimidinyl**, etc.), pyrazinyl, pyridazinyl, dihydropyridazinyl (e.g. 2,3-dihydropyridazinyl, 1,4-dihydropyridazinyl, etc.), tetrahydropyridazinyl (e.g. 2,3,4,5-tetrahydropyridazinyl, etc.) triazolyl (e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g.. . .

SUMM . . . 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), the much more preferred one may be pyridazinyl, dihydropyridazinyl, tetrahydropyridazinyl, pyrimidinyl, **dihydropyrimidinyl**, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrazolyl and imidazothiadiazolyl, and the most preferred one may be pyridazinyl, 2,3-dihydropyridazinyl, 1,4-dihydropyridazinyl, 2,3,4,5-tetrahydropyridazinyl, pyrimidinyl, 1,2-**dihydropyrimidinyl**, pyridyl, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridyl, pyrazolyl, and imidazo[2,1-b][1,3,4]thiadiazolyl.

SUMM . . . 4-oxo-1,4-dihydropyridine, etc.), dihydropyridine having oxo (e.g. 2-oxo-1,2,3,4-tetrahydropyridine, 4-oxo-1,2,3,4-tetrahydropyridine, etc.), tetrahydropyridine having oxo (e.g. 2-oxopiperidine, 4-oxopiperidine, etc.), pyrimidine having oxo (e.g.

2-oxo-1,2-**dihydropyrimidine**, etc.), **dihydropyrimidine** having oxo (e.g. 4-oxo-1,2,3,4-tetrahydropyrimidine, etc.), pyrazine having oxo (e.g. 2-oxo-1,2-dihydropyrazine, etc.), pyridazone having oxo (e.g. 3-oxo-3,4-dihydropyridazine, etc.), dihydropyridazine having oxo. . .

SUMM . . . ring, for example, azepine (e.g. 1H-azepine, etc.) imidazole, pyrazole, pyridine, dihydropyridine (e.g. 3,4-dihydropyridine, 5,6-dihydropyridine, etc.), tetrahydropyridine (e.g. 3,4,5,6-tetrahydropyridine, etc.) pyrimidine, **dihydropyrimidine** (e.g. 1,2-**dihydropyrimidine**, etc.), pyrazine, pyridazine, dihydropyridazine (e.g. 2,3-dihydropyridazine, 1,4-dihydropyridazine, etc.), tetrahydropyridazine (e.g. 2,3,4,5-tetrahydropyridazine, etc.), triazole (e.g. 4H-1,2,4-triazole, 1H-1,2,3-triazole, 2H-1,2,3-triazole, etc.), tetrazole (e.g.. . .

SUMM . . . atom(s), for example, azepin-1-yl (e.g. 1H-azepin-1-yl, etc.) 1-pyrrolyl, 1-pyrrolinyl, 1-imidazolyl, 1-pyrazolyl, dihydropyridin-1-yl (e.g. 1,2-dihydropyridin-1-yl, 1,4-dihydropyridin-1-yl, etc.), tetrahydropyridyl (e.g. 1,2,3,6-tetrahydropyridin-1-yl, etc.) **dihydropyrimidinyl** (e.g. 1,2-**dihydropyrimidin**-1-yl, etc.), dihydropyridazinyl (e.g. 2,3-dihydropyridazin-2-yl, 1,4-dihydropyridazin-1-yl, etc.), tetrahydropyridazinyl (e.g. 2,3,4,5-tetrahydropyridazin-2-yl, etc.) triazolyl (e.g. 4H-1,2,4-triazol-4-yl, 1H-1,2,3-triazol-1-yl, 2H-1,2,3-triazol-2-yl, etc.), tetrazol (e.g. 1H-tetrazol-1-yl, 2H-tetrazol-2-yl,. . .

SUMM . . . containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), the more preferred one may be dihydropyridazinyl, tetrahydropyridazinyl, **dihydropyrimidinyl**, dihydropyridyl, tetrahydropyridyl and pyrazolyl, and the most preferred one may be 2,3-dihydropyridazin-2-yl, 1,4-dihydropyridazin-1-yl, 2,3,4,5-tetrahydropyridazin-2-yl, 1,2-**dihydropyrimidin**-1-yl, 1,2-dihydropyridin-1-yl, 1,4-dihydropyridin-1-yl, 1,2,3,6-tetrahydropyridin-1-yl, and pyrazol-1-yl.

SUMM . . . as an eluent. The fractions containing the objective compound were combined and the solvent was evaporated in vacuo to give 3-(2-oxo-1,2-**dihydropyrimidin**-5-yl)-2-phenylpyrazolo[1,5-a]pyridine (0.44 g).

SUMM 3-[2-Oxo-1,2-**dihydropyrimidin**-4-yl)-2-phenylpyrazolo[1,5-a]pyridine was obtained according to a similar manner to that of Example 52.

SUMM 3-[1-(2-Methoxycarbonylethyl)-2-oxo-1,2-**dihydropyrimidin** -5-yl]-2-phenylpyrazolo[1,5-a]pyridine

L2 ANSWER 5 OF 5 USPATFULL on STN
AN 91:5140 USPATFULL
TI Pyrazolopyridine compound and processes for preparation thereof
IN Shiokawa, Youichi, Ibaraki, Japan
Akahane, Atsushi, Hyogo, Japan
Katayama, Hirohito, Nishinomiya, Japan
Mitsunaga, Takafumi, Ashiya, Japan
PA Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)
PI US 4985444 19910115 <--
AI US 1990-466929 19900118 (7)
PRAI GB 1989-1423 19890123
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Mary C.; Assistant Examiner: Dentz, Bernard I.
LREP Oblon, Spivak, McClelland, Maier & Neustadt
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2514
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to pyrazolopyridine compounds for the treatment of melancholia, heart failure, hypertension, renal insufficiency, edema, **obesity**, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, myocardiac infection, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack or angina pectoris, said compounds being of the formula ##STR1## wherein R.sup.1 is aryl, and

R.sup.2 is unsaturated heterocyclic group which contains at least one heteroatom selected from the group consisting of N, O and S, which may have one or more suitable substituent(s),

or a pharmaceutically acceptable salt thereof.

PI US 4985444 19910115 <--

AB The invention relates to pyrazolopyridine compounds for the treatment of melancholia, heart failure, hypertension, renal insufficiency, edema, **obesity**, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, myocardiac infection, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient. . .

SUMM . . . edema, nephrotic edema, hepatic edema, idiopathic edema, drug edema, acute angioneurotic edema, hereditary angioneurotic edema, carcinomatous ascites, gestational edema, etc.), **obesity**, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppresion, diabetes, myocardiac infarction, thrombosis (e.g. arterial thrombosis, cerebral thrombosis, etc.), obstruction,. . .

SUMM . . . example, azepinyl (e.g. 1H-azepinyl, etc.) pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl (e.g. 1,2-dihydropyridyl, 1,4-dihydropyridyl, etc.), tetrahydropyridyl (e.g. 1,2,3,6-tetrahydropyridyl, etc.) pyrimidinyl, **dihydropyrimidinyl** (e.g. 1,2-**dihydropyrimidinyl**, etc.), pyrazinyl, pyridazinyl, dihydropyridazinyl (e.g. 2,3-dihydropyridazinyl, 1,4-dihydropyridazinyl, etc.), tetrahydropyridazinyl (e.g. 2,3,4,5-tetrahydropyridazinyl, etc.) triazolyl (e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g.. . .

SUMM . . . 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), the much more preferred one may be pyridazinyl, dihydropyridazinyl, tetrahydropyridazinyl, pyrimidinyl, **dihydropyrimidinyl**, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrazolyl and imidazothiadiazolyl, and the most preferred one may be pyridazinyl, 2,3-dihydropyridazinyl, 1,4-dihydropyridazinyl, 2,3,4,5-tetrahydropyridazinyl, pyrimidinyl, 1,2-**dihydropyrimidinyl**, pyridyl, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridyl, pyrazolyl, and imidazo[2,1-b][1,3,4]thiadiazolyl.

SUMM . . . 4-oxo-1,4-dihydropyridine, etc.), dihydropyridine having oxo (e.g. 2-oxo-1,2,3,4-tetrahydropyridine, 4-oxo-1,2,3,4-tetrahydropyridine, etc.), tetrahydropyridine having oxo (e.g. 2-oxopiperidine, 4-oxopiperidine, etc.), pyrimidine having oxo (e.g. 2-oxo-1,2-**dihydropyrimidine**, etc.), **dihydropyrimidine** having oxo (e.g. 4-oxo-1,2,3,4-tetrahydropyrimidine, etc.), pyrazine having oxo (e.g. 2-oxo-1,2-dihydropyrazine, etc.), pyridazine having oxo (e.g. 3-oxo-3,4-dihydropyridazine, etc.), dihydropyridazine having oxo. . .

SUMM . . . ring, for example, azepine (e.g. 1H-azepine, etc.) imidazole, pyrazole, pyridine, dihydropyridine (e.g. 3,4-dihydropyridine, 5,6-dihydropyridine, etc.), tetrahydropyridine (e.g. 3,4,5,6-tetrahydropyridine, etc.) pyrimidine, **dihydropyrimidine** (e.g. 1,2-**dihydropyrimidine**, etc), pyrazine, pyridazine, dihydropyridazine (e.g. 2,3-dihydropyridazine, 1,4-dihydropyridazine, etc.), tetrahydropyridazine (e.g. 2,3,4,5-tetrahydropyridazine, etc.), triazole (e.g. 4H-1,2,4-triazole, 1H-1,2,3-triazole, 2H-1,2,3-triazole, etc.), tetrazole. . .

SUMM . . . atom(s), for example, azepin-1-yl (e.g. 1H-azepin-1-yl, etc.) 1-pyrrolyl, 1-pyrrolinyl, 1-imidazolyl, 1-pyrazolyl, dihydropyridin-1-yl (e.g. 1,2-dihydropyridin-1-yl, 1,4-dihydropyridin-1-yl, etc.), tetrahydropyridyl (e.g. 1,2,3,6-tetrahydropyridin-1-yl, etc.) **dihydropyrimidinyl** (e.g. 1,2-**dihydropyrimidin**-1-yl, etc.), dihydropyridazinyl (e.g. 2,3-dihydropyridazin-2-yl, 1,4-dihydropyridazin-1-yl, etc.), tetrahydropyridazinyl (e.g. 2,3,4,5-tetrahydropyridazin-2-yl, etc.) triazolyl (e.g. 4H-1,2,4-triazol-4-yl, 1H-1,2,3-triazol-1-yl, 2H-1,2,3-triazol-2-yl, etc.), tetrazol (e.g. 1H-tetrazol-1-yl, 2H-tetrazol-2-yl,. . .

SUMM . . . containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), the more preferred one may be dihydropyridazinyl, tetrahydropyridazinyl, **dihydropyrimidinyl**, dihydropyridYl, tetrahydropyridyl and pyrazolyl, and the most preferred one may be 2,3-dihydropyridazin-2-yl, 1,4-dihydropyridazin-1-yl, 2,3,4,5-tetrahydropyridazin-2-yl, 1,2-**dihydropyrimidin**-1-yl, 1,2-dihydropyridin-1-yl, 1,4-dihydropyridin-1-yl, 1,2,3,6-tetrahydropyridin-1-yl, and pyrazol-1-yl.

DETD . . . as an eluent. The fractions containing the objective compound were combined and the solvent was evaporated in vacuo to give 3-(2-oxo-1,2-**dihydropyrimidin**-5-yl)-2-phenylpyrazolo[1,5-a]pyridine (0.44 g).

DETD 3-(2-Oxo-1,2-**dihydropYrimidin**-4-yl)-2-phenylpyrazolo[1,5-a]pyridine was obtained according to a similar manner to that of Example 52.

DETD 3-[1-(2-Methoxycarbonylethyl)-2-oxo-1,2-**dihydropyrimidin**-5-yl]-2-phenylpyrazolo[1,5-a]pyridine

DETD 3-[1-(2-Methoxycarbonylethyl)-2-oxo-1,2-**dihydropyrimidin**-4-yl]-2-phenylpyrazolo[1,5-a]pyridine

CLM What is claimed is:

3. A compound of claim 2, wherein R.sup.1 is phenyl, and R.sup.2 is pyridazinyl, dihydropyridazinyl, tetrahydropyridazinyl, pyrimidinyl, **dihydropyrimidinyl**, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrazolyl or imidazothiadiazolyl, each of which may have one or more suitable substituent(s) selected from a group. . .

4. A compound of claim 3, wherein R.sup.2 is pyridazinyl, dihydropyridazinyl, tetrahydropyridazinyl, pyrimidinyl, **dihydropyrimidinyl**, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrazolyl or imidazothiadiazolyl, each of which may have 1 to 4 suitable substituent(s) selected from a group. . .

5. A compound of claim 4, wherein R.sup.2 is pyridazinyl, dihydropyridazinyl, tetrahydropyridazinyl, pyrimidinyl, **dihydropyrimidinyl**, pyridyl, dihydropyridyl, tetrahydropyridyl, pyrazolyl or imidazothiadiazolyl, each of which may have 1 to 4 suitable substituent(s) selected from a group. . .

. . . pyrimidinyl which may have 1 suitable substituent selected from a group consisting of lower alkyl, amino, halogen and lower alkoxy; **dihydropyrimidinyl** which may have 1 or 2 suitable substituent(s) selected from a group consisting of lower alkoxycarbonyl(lower)alkyl and oxo; pyridyl which. . .

15. A method for the treatment of melancholia, heart failure, hypertension, renal insufficiency, edema, **obesity**, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppresion, diabetes, myocardial infarction, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient. . .

=> d his

(FILE 'HOME' ENTERED AT 12:12:40 ON 29 JUL 2003)

```
     FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT,
     CAPLUS, CEN, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL,
     EMBASE, ESBIOBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF,
     MEDLINE, NAPRALERT, NLDB, NUTRACEUT, ...' ENTERED AT 12:12:54 ON 29 JUL
     2003
L1            51 S OBESITY AND DIHYDROPYRIMIDIN?
L2             5 S L1 AND PD<1999

=> file uspat full
'USPAT' IS AN AMBIGUOUS FILE OR CLUSTER NAME
 USPATALL          - US Patent Full Text Cluster
 USPAT2            - U.S. Patents Latest Publications from 2001 - present
 USPATFULL         - U.S. Patents Original Publications from 1971 - present
ENTER FILE OR CLUSTER NAME (IGNORE):file uspatfull
'FILE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):IGNORE
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    58.98      59.19

FILE 'USPATFULL' ENTERED AT 12:18:32 ON 29 JUL 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'ADISCTI' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'CEN' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CFR' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 U.S. Govt Printing Office (USGPO)

FILE 'DIOGENES' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 FOI Services, Inc. (FOI)

FILE 'DRUGNL' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'FEDREGFULL' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 U.S. Govt Printing Office (USGPO)

FILE 'IMSPROFILES' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd.

FILE 'INVESTEXT' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 Thomson Financial Services, Inc. (TFS)

FILE 'NLDB' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'NUTRACEUT' ENTERED AT 12:18:32 ON 29 JUL 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.
```

```
FILE 'PHARMAML' ENTERED AT 12:18:32 ON 29 JUL 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 12:18:32 ON 29 JUL 2003
COPYRIGHT (C) 2003 Kenneth Mason Publications Ltd.

FILE 'USPAT2' ENTERED AT 12:18:32 ON 29 JUL 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> File uspatfull
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              26.59      85.78

FILE 'USPATFULL' ENTERED AT 12:18:49 ON 29 JUL 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 29 Jul 2003 (20030729/PD)
FILE LAST UPDATED: 29 Jul 2003 (20030729/ED)
HIGHEST GRANTED PATENT NUMBER: US6601238
HIGHEST APPLICATION PUBLICATION NUMBER: US2003140390
CA INDEXING IS CURRENT THROUGH 29 Jul 2003 (20030729/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 29 Jul 2003 (20030729/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2003
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2003

>>>  USPAT2 is now available.  USPATFULL contains full text of the     <<<
>>>  original, i.e., the earliest published granted patents or         <<<
>>>  applications.  USPAT2 contains full text of the latest US         <<<
>>>  publications, starting in 2001, for the inventions covered in     <<<
>>>  USPATFULL.  A USPATFULL record contains not only the original     <<<
>>>  published document but also a list of any subsequent              <<<
>>>  publications.  The publication number, patent kind code, and      <<<
>>>  publication date for all the US publications for an invention     <<<
>>>  are displayed in the PI (Patent Information) field of USPATFULL   <<<
>>>  records and may be searched in standard search fields, e.g., /PN, <<<
>>>  /PK, etc.                                                         <<<

>>>  USPATFULL and USPAT2 can be accessed and searched together        <<<
>>>  through the new cluster USPATALL.  Type FILE USPATALL to          <<<
>>>  enter this cluster.                                               <<<
>>>                                                                    <<<
>>>  Use USPATALL when searching terms such as patent assignees,       <<<
>>>  classifications, or claims, that may potentially change from     <<<
>>>  the earliest to the latest publication.                           <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s obesity and dihydropyrimidin?
          8792 OBESITY
           635 DIHYDROPYRIMIDIN?
```

L3 36 OBESITY AND DIHYDROPYRIMIDIN?

=> d l3 1-36 bib, ab

L3 ANSWER 1 OF 36 USPATFULL on STN
AN 2003:201441 USPATFULL
TI A2B adenosine receptor antagonists
IN Kalla, Rao, Mountain View, CA, UNITED STATES
Perry, Thao, San Jose, CA, UNITED STATES
Elzein, Elfatih, Fremont, CA, UNITED STATES
Varkhedkar, Vaibhav, San Diego, CA, UNITED STATES
Li, Xiaofen, Palo Alto, CA, UNITED STATES
Ibrahim, Prabha, Mountain View, CA, UNITED STATES
Palle, Venkata, Gurgaon, INDIA
Xiao, Dengming, Longmont, CO, UNITED STATES
Zablocki, Jeff, Mountain View, CA, UNITED STATES
PI US 2003139428 A1 20030724
AI US 2002-290921 A1 20021108 (10)
PRAI US 2001-348222P 20011109 (60)
US 2002-401408P 20020805 (60)
DT Utility
FS APPLICATION
LREP Brian Lewis, CV Therapeutics, Inc., 3172 Porter Drive, Palo Alto, CA, 94304
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3235
AB Disclosed are novel compounds that are A.sub.2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

L3 ANSWER 2 OF 36 USPATFULL on STN
AN 2003:188496 USPATFULL
TI Inhibitors of glycogen synthase kinase 3
IN Nuss, John M., Danville, CA, UNITED STATES
Harrison, Stephen D., Berkeley, CA, UNITED STATES
Ring, David B., Palo Alto, CA, UNITED STATES
Boyce, Rustum S., San Francisco, CA, UNITED STATES
Brown, Sean P., Emeryville, CA, UNITED STATES
Goff, Dane A., Redwood City, CA, UNITED STATES
Johnson, Kirk W., Moraga, CA, UNITED STATES
Pfister, Keith B., El Cerrito, CA, UNITED STATES
Ramurthy, Savithri, Walnut Creek, CA, UNITED STATES
Renhowe, Paul A., Danville, CA, UNITED STATES
Seely, Lynn, Burlingame, CA, UNITED STATES
Subramanian, Sharadha, San Ramon, CA, UNITED STATES
Wagman, Allan S., Oakland, CA, UNITED STATES
Zhou, Xiaohui A., Berkeley, CA, UNITED STATES
PA Chiron Corporation (U.S. corporation)
PI US 2003130289 A1 20030710
AI US 2002-309535 A1 20021203 (10)
RLI Division of Ser. No. US 1999-336098, filed on 18 Jun 1999, GRANTED, Pat. No. US 6489344
PRAI US 1998-89978P 19980619 (60)
DT Utility
FS APPLICATION
LREP CHIRON CORPORATION, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097
CLMN Number of Claims: 88
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 10031
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, **obesity**, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

L3 ANSWER 3 OF 36 USPATFULL on STN
AN 2003:180749 USPATFULL
TI Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
IN Mack, David H., Menlo Park, CA, UNITED STATES
Gish, Kurt C., San Francisco, CA, UNITED STATES
PA Eos Biotechnology, Inc., South San Francisco, CA (U.S. corporation)
PI US 2003124579 A1 20030703
AI US 2002-235399 A1 20020904 (10)
PRAI US 2002-372246P 20020412 (60)
US 2001-350666P 20011113 (60)
US 2001-317544P 20010905 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7005
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described herein are genes whose expression are up-regulated or down-regulated in ovarian cancer. Related methods and compositions that can be used for diagnosis and treatment of ovarian cancer are disclosed. Also described herein are methods that can be used to identify modulators of ovarian cancer.

L3 ANSWER 4 OF 36 USPATFULL on STN
AN 2003:146816 USPATFULL
TI Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
IN Edmondson, Scott D., New York, NJ, UNITED STATES
Fisher, Michael H., Ringoes, NJ, UNITED STATES
Kim, Dooseop, Westfield, NJ, UNITED STATES
Maccoss, Malcolm, Freehold, NJ, UNITED STATES
Parmee, Emma R., Scotch Plains, NJ, UNITED STATES
Weber, Ann E., Scotch Plains, NJ, UNITED STATES
Xu, Jinyou, Scotch Plains, NJ, UNITED STATES
PI US 2003100563 A1 20030529
AI US 2002-189603 A1 20020705 (10)
PRAI US 2001-303474P 20010706 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1910
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

L3 ANSWER 5 OF 36 USPATFULL on STN
AN 2003:120142 USPATFULL
TI DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
IN Borowsky, Beth, Montclair, NJ, UNITED STATES
Blackburn, Thomas P., Hoboken, NJ, UNITED STATES
Ogozalek, Kristine, Rochelle Park, NJ, UNITED STATES
PI US 2003082623 A1 20030501
AI US 2001-899732 A1 20010705 (9)
RLI Continuation-in-part of Ser. No. US 2000-610635, filed on 5 Jul 2000, PENDING Continuation-in-part of Ser. No. WO 1999-US31169, filed on 30 Dec 1999, UNKNOWN Continuation-in-part of Ser. No. US 1998-224426, filed on 31 Dec 1998, PATENTED
DT Utility
FS APPLICATION
LREP Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036
CLMN Number of Claims: 207
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 12109
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention provides a method of modifying the feeding behavior of a subject which comprises administering to the subject an amount of an MCH1 antagonist effective to decrease the body mass of the subject and/or decrease the consumption of food by the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's depression and/or anxiety.

L3 ANSWER 6 OF 36 USPATFULL on STN
AN 2003:120054 USPATFULL
TI Methods for genetic analysis of DNA to detect sequence variances
IN Stanton, Vincent P., JR., Belmont, MA, UNITED STATES
PI US 2003082537 A1 20030501
AI US 2001-863733 A1 20010523 (9)
RLI Continuation-in-part of Ser. No. US 2000-697028, filed on 25 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-696998, filed on 25 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2001-967013, filed on 28 Sep 2001, PENDING
PRAI US 2000-206613P 20000523 (60)
DT Utility

FS APPLICATION
LREP ANITA L. MEIKLEJOHN, PH.D., Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 72
ECL Exemplary Claim: 1
DRWN 43 Drawing Page(s)
LN.CNT 5382
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for determing genotypes and haplotypes of genes are described. Also described are single nucleotide polymorphisms and haplotypes in the ApoE gene and methods of using that information.

L3 ANSWER 7 OF 36 USPATFULL on STN
AN 2003:112968 USPATFULL
TI DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
IN Forray, Carlos, Paramus, NJ, UNITED STATES
Salon, John A., Santa Paula, CA, UNITED STATES
Laz, Thomas M., Parlin, NJ, UNITED STATES
Nagorny, Raisa, Fairlawn, NY, UNITED STATES
Wilson, Amy E., Woodstock, NY, UNITED STATES
PI US 2003077701 A1 20030424
AI US 2001-29314 A1 20011220 (10)
RLI Continuation of Ser. No. US 2001-899732, filed on 5 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2000-610635, filed on 5 Jul 2000, ABANDONED Continuation-in-part of Ser. No. WO 1999-US31169, filed on 30 Dec 1999, UNKNOWN Continuation-in-part of Ser. No. US 1998-224426, filed on 31 Dec 1998, GRANTED, Pat. No. US 6221613
DT Utility
FS APPLICATION
LREP John P. White, Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036
CLMN Number of Claims: 207
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 12095
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention provides a method of modifying the feeding behavior of a subject which comprises administering to the subject an amount of an MCH1 antagonist effective to decrease the body mass of the subject and/or decrease the consumption of food by the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's depression and/or anxiety.

L3 ANSWER 8 OF 36 USPATFULL on STN
AN 2003:106190 USPATFULL
TI Restriction enzyme genotyping
IN Olson, Jeffrey, Chelmsford, MA, UNITED STATES
Zillmann, Martin, Shrewsbury, MA, UNITED STATES

Stanton, Vincent P., JR., Belmont, MA, UNITED STATES
PI US 2003073101 A1 20030417
AI US 2002-116420 A1 20020404 (10)
RLI Continuation-in-part of Ser. No. US 2001-863733, filed on 23 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-697028, filed on 25 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-696998, filed on 25 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-697013, filed on 25 Oct 2000, PENDING
PRAI US 2000-206613P 20000523 (60)
DT Utility
FS APPLICATION
LREP ANITA L. MEIKLEJOHN, PH.D., Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 45 Drawing Page(s)
LN.CNT 4670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for determing genotypes and haplotypes of genes are described. Also described are single nucleotide polymorphisms and haplotypes in the ApoE gene and methods of using that information.

L3 ANSWER 9 OF 36 USPATFULL on STN
AN 2003:100150 USPATFULL
TI Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
IN Marzabadi, Mohammad R., Ridgewood, NJ, UNITED STATES
Wetzel, John, Fairlawn, NJ, UNITED STATES
DeLeon, John E., North Bergen, NJ, UNITED STATES
Lagu, Bharat, Belle Mead, NJ, UNITED STATES
Gluchowski, Charles, Danville, CA, UNITED STATES
Noble, Stewart, Lake Forest, IL, UNITED STATES
Nagarathnam, Dhanapalan, Bethany, CT, UNITED STATES
PI US 2003069261 A1 20030410
AI US 2001-899635 A1 20010705 (9)
PRAI US 2000-216218P 20000705 (60)
DT Utility
FS APPLICATION
LREP Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036
CLMN Number of Claims: 90
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5622
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the

invention, the feeding disorder is bulimia, bulimia nervosa or **obesity**.

L3 ANSWER 10 OF 36 USPATFULL on STN
AN 2003:81737 USPATFULL
TI Tricyclic **dihydropyrimidine** potassium channel openers
IN Holladay, Mark W., Tucson, AZ, United States
Carroll, William A., Evanston, IL, United States
Drizin, Irene, Wadsworth, IL, United States
Yi, Lin, Gurnee, IL, United States
Zhang, Henry Q., Grayslake, IL, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 6538000 B1 20030325
AI US 2000-709923 20001110 (9)
PRAI US 1999-166491P 19991119 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Liu, Hong
LREP Chen, Portia, Ward, Michael J.
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3017
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) ##STR1##

are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.

L3 ANSWER 11 OF 36 USPATFULL on STN
AN 2003:78501 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2003054421 A1 20030320
AI US 2002-102806 A1 20020322 (10)
RLI Continuation of Ser. No. US 2001-925298, filed on 10 Aug 2001, PENDING
Continuation-in-part of Ser. No. WO 2000-US5881, filed on 8 Mar 2000, UNKNOWN
PRAI US 1999-124270P 19990312 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 20141
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel ovarian cancer and/or breast cancer related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian and/or breast antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian and/or breast polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian and/or breast nucleic acid molecules are provided encoding novel ovarian and/or breast polypeptides. Novel ovarian and/or breast polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors,

host cells, and recombinant and synthetic methods for producing human ovarian and/or breast polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

L3 ANSWER 12 OF 36 USPATFULL on STN
AN 2003:30941 USPATFULL
TI Heterocyclic **dihydropyrimidine** compounds
IN Atwal, Karnail S., Newtown, PA, UNITED STATES
Vaccaro, Wayne, Yardley, PA, UNITED STATES
Lloyd, John, Yardley, PA, UNITED STATES
Finlay, Heather, Lawrenceville, NJ, UNITED STATES
Yan, Lin, Princeton, NJ, UNITED STATES
Bhandaru, Rao S., Belle Mead, NJ, UNITED STATES
PI US 2003022890 A1 20030130
AI US 2000-729731 A1 20001205 (9)
PRAI US 2000-236037P 20000928 (60)
US 1999-169091P 19991206 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7238
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel heterocyclic **dihydropyrimidine** compounds useful as inhibitors of potassium channel function (especially inhibitors of the K.sub.v1 subfamily of voltage gated K.sup.+ channels, especially inhibitors K.sub.v1.5 which has been linked to the ultra-rapidly activating delayed rectifier K.sup.+ current I.sub.Kur), methods of using such compounds in the prevention and treatment of arrhythmia and I.sub.Kur-associated conditions, and pharmaceutical compositions containing such compounds.

L3 ANSWER 13 OF 36 USPATFULL on STN
AN 2003:17975 USPATFULL
TI New monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them
IN Iqbal, Javed, Hyderabad, INDIA
Madhavan, Gurram Ranga, Hyderabad, INDIA
Das, Saibal Kumar, Hyderabad, INDIA
Bhunia, Debnath, Hyderabad, INDIA
Chakrabarti, Ranjan, Hyderabad, INDIA
Rajagopalan, Ramanujam, Hyderabad, INDIA
PA DR. REDDY'S LABORATORIES LTD. (non-U.S. corporation)
PI US 2003013729 A1 20030116
AI US 2002-119300 A1 20020408 (10)
PRAI IN 2001-3012001 20010409
DT Utility
FS APPLICATION
LREP Ladas & Parry, 26 West 61 Street, New York, NY, 10023
CLMN Number of Claims: 22

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4579
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel hypolipidemic, antihyperglycemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel .beta.-aryl-.alpha.-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. ##STR1##

L3 ANSWER 14 OF 36 USPATFULL on STN
AN 2003:13310 USPATFULL
TI Carboxylic acid derivatives and drugs containing the same as the active ingredient
IN Tajima, Hisao, Osaka, JAPAN
Nakayama, Yoshisuke, Osaka, JAPAN
Fukushima, Daikichi, Osaka, JAPAN
PA ONO Pharmaceutical Co., Ltd., Osaka, JAPAN (non-U.S. corporation)
PI US 6506757 B1 20030114
WO 9946232 19990916
AI US 2000-623913 20000911 (9)
WO 1999-JP1134 19990309
20000911 PCT 371 date
PRAI JP 1998-58444 19980310
JP 1998-87560 19980331
DT Utility
FS GRANTED
EXNAM Primary Examiner: Rao, Deepak R.
LREP Sughrue Mion, PLLC
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 4481
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I) ##STR1##

(wherein all symbols are as defined in the specification), a non-toxic acid thereof or a hydrate thereof as active ingredient. Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating metabolic disorders (diabetes, **obesity**, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diseases or syndrome X.

L3 ANSWER 15 OF 36 USPATFULL on STN
AN 2002:317438 USPATFULL
TI Inhibitors of glycogen synthase kinase 3
IN Nuss, John M., Danville, CA, United States
Harrison, Stephen D., Berkeley, CA, United States
Ring, David B., Palo Alto, CA, United States
Boyce, Rustum S., San Francisco, CA, United States

Brown, Sean P., Emeryville, CA, United States
Goff, Dane A., Redwood City, CA, United States
Johnson, Kirk W., Moraga, CA, United States
Pfister, Keith B., El Cerrito, CA, United States
Ramurthy, Savithri, Walnut Creek, CA, United States
Renhowe, Paul A., Danville, CA, United States
Seely, Lynn, Burlingame, CA, United States
Subramanian, Sharadha, San Ramon, CA, United States
Wagman, Allan S., Oakland, CA, United States
Zhou, Xiaohui A., Berkeley, CA, United States
PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 6489344 B1 20021203
AI US 1999-336098 19990618 (9)
PRAI US 1998-89978P 19980618 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Ford, John M.
LREP Shelton, Dennis K., Lentini, David P., Blackburn, Robert P.
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 10002
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, **obesity**, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

L3 ANSWER 16 OF 36 USPATFULL on STN
AN 2002:301630 USPATFULL
TI Pharmaceutically acceptable salts of heterocyclic compounds
IN Gaddam, Om Reddy, Hyderabad, INDIA
Batchu, Chandra Sekhar, Hyderabad, INDIA
Potlapally, Rajender Kumar, Hyderabad, INDIA
Mamillapalli, Ramabhadra Sarma, Hyderabad, INDIA
Paraselli, Bheema Rao, Hyderabad, INDIA
Mamidi, Naga Venkata Srinivasa Rao, Hyderabad, INDIA
PA DR. REDDY'S LABORATORIES LTD. (non-U.S. corporation)
PI US 2002169175 A1 20021114
AI US 2002-67094 A1 20020204 (10)
PRAI US 2001-266595P 20010205 (60)
DT Utility
FS APPLICATION
LREP LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023
CLMN Number of Claims: 65
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3785
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to pharmaceutically acceptable salts of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. ##STR1##

L3 ANSWER 17 OF 36 USPATFULL on STN

AN 2002:295180 USPATFULL
TI Estrogen receptor modulators
IN DiNinno, Frank P., Old Bridge, NJ, UNITED STATES
Wu, Jane Y., Marlboro, NJ, UNITED STATES
Kim, Seongkon, Holmdel, NJ, UNITED STATES
Chen, Helen Y., Livingston, NJ, UNITED STATES
PI US 2002165226 A1 20021107
AI US 2002-120723 A1 20020411 (10)
RLI Continuation-in-part of Ser. No. WO 2001-US42735, filed on 15 Oct 2001, UNKNOWN
PRAI US 2000-241582P 20001019 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, **obesity**, incontinence, and cancer, in particular of the breast, uterus and prostate.

L3 ANSWER 18 OF 36 USPATFULL on STN
AN 2002:290732 USPATFULL
TI Methods for genetic analysis of DNA using biased amplification of polymorphic sites
IN Stanton, Jr., Vincent P., Belmont, MA, United States
PA Variagenics, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6475736 B1 20021105
AI US 2000-696998 20001025 (9)
PRAI US 2000-206613P 20000523 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Benzion, Gary; Assistant Examiner: Chunduru, Suryaprabha
LREP Fish & Richardson, P.C.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 35 Drawing Page(s)
LN.CNT 4417
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for determining genotypes and haplotypes of genes are described. Also described are single nucleotide polymorphisms and haplotypes in the ApoE gene and methods of using that information.

L3 ANSWER 19 OF 36 USPATFULL on STN
AN 2002:280641 USPATFULL
TI Inhibitors of glycogen synthase kinase 3
IN Nuss, John M., Danville, CA, UNITED STATES
Harrison, Stephen D., Albany, CA, UNITED STATES
Ring, David B., Palo Alto, CA, UNITED STATES
Boyce, Rustum S., San Francisco, CA, UNITED STATES
Johnson, Kirk, Moraga, CA, UNITED STATES

Pfister, Keith B., San Ramon, CA, UNITED STATES
Ramurthy, Savithri, Walnut Creek, CA, UNITED STATES
Seely, Lynn, Burlingame, CA, UNITED STATES
Wagman, Allan S., Oakland, CA, UNITED STATES
Desai, Manjo, Pleasant Hill, CA, UNITED STATES
Levine, Barry H., Lafayyette, CA, UNITED STATES
PI US 2002156087 A1 20021024
AI US 2001-949035 A1 20010906 (9)
RLI Continuation-in-part of Ser. No. US 1999-336038, filed on 18 Jun 1999, GRANTED, Pat. No. US 6417185
PRAI US 2000-230480P 20000906 (60)
DT Utility
FS APPLICATION
LREP CHRISTENSEN, O'CONNOR, JOHNSON, KINDNESS, PLLC, 1420 FIFTH AVENUE, SUITE 2800, SEATTLE, WA, 98101-2347
CLMN Number of Claims: 103
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 10429
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, **obesity**, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

L3 ANSWER 20 OF 36 USPATFULL on STN
AN 2002:213697 USPATFULL
TI Genome-based personalized medicine
IN Papadopoulos, Nickolas, Brookline, MA, UNITED STATES
Yan, Hai, Baltimore, MD, UNITED STATES
Vogelstein, Bert, Baltimore, MD, UNITED STATES
Kinzler, Kenneth W., Bel Air, MD, UNITED STATES
PI US 2002115073 A1 20020822
AI US 2001-784305 A1 20010216 (9)
DT Utility
FS APPLICATION
LREP BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001
CLMN Number of Claims: 70
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1187
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Individual alleles can be isolated from every chromosome within somatic cell hybrids generated from a single fusion event. Nucleic acids or proteins from the hybrids can be analyzed for polymorphisms to provide unambiguous determinations. Information thus obtained can be used to develop and implement personalized medical interventions for individuals having particular polymorphic markers.

L3 ANSWER 21 OF 36 USPATFULL on STN
AN 2002:192144 USPATFULL
TI New monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
IN Gurram, Ranga Madhavan, Ameerpet Hyderabad, INDIA
Akella, Venkateswarlu, Ameerpet Hyderabad, INDIA
Ramanujam, Rajagopalan, Ameerpet Hyderabad, INDIA

Chakrabarti, Ranjan, Ameerpet Hyderabad, INDIA
Misra, Parimal, Ameerpet Hyderabad, INDIA
Lohray, Vidya Bhushan, Ameerpet Hyderabad, INDIA
Lohray, Braj Bhushan, Ameerpet Hyderabad, INDIA
Paraselli, Rao Bheema, Ameerpet Hyderabad, INDIA
PA DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR, INC. (non-U.S. corporation)
PI US 2002103215 A1 20020801
AI US 2002-41384 A1 20020108 (10)
RLI Division of Ser. No. US 2000-507371, filed on 18 Feb 2000, PATENTED
Continuation-in-part of Ser. No. US 1998-179002, filed on 26 Oct 1998, PENDING
PRAI IN 1997-242097 19971027
US 1998-82825P 19980423 (60)
DT Utility
FS APPLICATION
LREP Ladas & Parry, 26 West 61st Street, New York, NY, 10023
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3465
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel .beta.-aryl-.alpha.-oxysubstituted alkylcarboxylic acids of the general formula (I), ##STR1##

their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to novel intermediates, processes for their preparation and their use in the preparation of compounds of formula (I).

L3 ANSWER 22 OF 36 USPATFULL on STN
AN 2002:192140 USPATFULL
TI TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES
IN Gong, Baoqing, Shoreline, WA, UNITED STATES
Klein, J. Peter, Vashon, WA, UNITED STATES
Coon, Michael, Seattle, WA, UNITED STATES
PA Cell Therapeutics, Inc. (U.S. corporation)
PI US 2002103211 A1 20020801
US 6586429 B2 20030701
AI US 2000-725016 A1 20001129 (9)
DT Utility
FS APPLICATION
LREP WILLEM F. GADIANO, ESQ., MCDERMOTT, WILL & EMERY, 600 13th Street, N.W., Washington, DC, 20005
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2719
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.

L3 ANSWER 23 OF 36 USPATFULL on STN
AN 2002:78774 USPATFULL
TI Zwitterionic tachykinin receptor antagonists
IN Finke, Paul E., Milltown, NJ, UNITED STATES
Meurer, Laura C., Scotch Plains, NJ, UNITED STATES
Mills, Sander G., Scotch Plains, NJ, UNITED STATES
MacCoss, Malcolm, Freehold, NJ, UNITED STATES
Qi, Hongbo, Edison, NJ, UNITED STATES
PI US 2002042431 A1 20020411
US 6479518 B2 20021112
AI US 2001-957965 A1 20010921 (9)
PRAI US 2000-234490P 20000922 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3984
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to certain novel compounds represented by structural formula I: ##STR1##

or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12 R.sup.13, Q, W, X, Y and Z are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of psychiatric disorders including depression and anxiety.

L3 ANSWER 24 OF 36 USPATFULL on STN
AN 2002:75442 USPATFULL
TI Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
IN Gurram, Ranga Madhavan, Ameerpet Hyderabad, INDIA
Akella, Venkateswarlu, Ameerpet Hyderabad, INDIA
Ramanujam, Rajagopalan, Ameerpet Hyderabad, INDIA
Chakrabarti, Ranjan, Ameerpet Hyderabad, INDIA
Misra, Parimal, Ameerpet Hyderabad, INDIA
Lohray, Vidya Bhushan, Ameerpet Hyderabad, INDIA
Lohray, Braj Bhushan, Ameerpet Hyderabad, INDIA
Paraselli, Rao Bheema, Ameerpet Hyderabad, INDIA
PA Dr. Reddy's Research Foundation, INDIA (non-U.S. corporation)
Reddy-Cheminor Inc., Ridgewood, NJ, United States (U.S. corporation)
PI US 6369067 B1 20020409
AI US 2000-507371 20000218 (9)
RLI Continuation-in-part of Ser. No. US 1998-179002, filed on 26 Oct 1998
PRAI IN 1997-242097 19971027
US 1998-82825P 19980423 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.
LREP Ladas & Parry
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 3441
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel .beta.-aryl-.alpha.-oxysubstituted alkylcarboxylic acids of the general formula (I), ##STR1##

their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to novel intermediates, processes for their preparation and their use in the preparation of compounds of formula (I).

L3 ANSWER 25 OF 36 USPATFULL on STN
AN 2002:72627 USPATFULL
TI Nucleic, acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002039764 A1 20020404
AI US 2001-925298 A1 20010810 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US5881, filed on 8 Mar 2000, UNKNOWN
PRAI US 1999-124270P 19990312 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 20087
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel ovarian cancer and/or breast cancer related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian and/or breast antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian and/or breast polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian and/or breast nucleic acid molecules are provided encoding novel ovarian and/or breast polypeptides. Novel ovarian and/or breast polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian and/or breast polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention.

The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

L3 ANSWER 26 OF 36 USPATFULL on STN
AN 2002:63746 USPATFULL
TI Solid phase synthesis of heterocycles
IN Munoz, Benito, San Diego, CA, United States
Chen, Chixu, Carlsbad, CA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6362009 B1 20020326
AI US 1997-975944 19971121 (8)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Venkat, Jyothsna; Assistant Examiner: Garcia, Maurie E.
LREP Lee, Shu Muk, Rose, David L.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 4604
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for solid phase and combinatorial synthesis using a resin activation/capture approach are provided. In particular, methods for the production of dihydropyridones, N-acyidihydropyridones, tetrahydropyridones, pyridines, aminopyridines, N-acyltetrahydropyridines and tetrahydropyridines compounds and libraries containing such compounds are provided. Methods for screening the libraries and compounds and pharmaceutical compositions containing compounds prepared by the methods are provided.

L3 ANSWER 27 OF 36 USPATFULL on STN
AN 2002:55155 USPATFULL
TI Human single nucleotide polymorphisms
IN Cargill, Michele, Gaithersburg, MD, UNITED STATES
Ireland, James S., Gaithersburg, MD, UNITED STATES
Lander, Eric S., Cambridge, MA, UNITED STATES
PA Whitehead Institute for Biomedical Research, Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2002032319 A1 20020314
AI US 2001-801274 A1 20010307 (9)
PRAI US 2000-187510P 20000307 (60)
US 2000-206129P 20000522 (60)
DT Utility
FS APPLICATION
LREP HAMILTON BROOK SMITH AND REYNOLDS, P.C., TWO MILITIA DR, LEXINGTON, MA, 02421-4799
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8981
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides nucleic acid segments of the human genome, particularly nucleic acid segments from genes including polymorphic sites. Allele-specific primers and probes hybridizing to regions flanking or containing these sites are also provided. The nucleic acids, primers and probes are used in applications such as phenotype correlations, forensics, paternity testing, medicine and genetic analysis.

L3 ANSWER 28 OF 36 USPATFULL on STN
AN 2002:50972 USPATFULL

TI Pyrazolopyridine adenosine antagonists
IN Akahane, Atsushi, Hyogo, JAPAN
Nishimura, Shintaro, Settsu, JAPAN
Itani, Hiromichi, Hyogo, JAPAN
Durkin, Kieran P. M., Folsom, CA, United States
PA Fujisawa Pharmaceutical Co., Ltd., Osaka, JAPAN (non-U.S. corporation)
PI US 6355640 B1 20020312
AI US 1998-72696 19980506 (9)
RLI Continuation of Ser. No. US 663119, now patented, Pat. No. US 5773530
PRAI GB 1993-26524 19931229
GB 1994-4323 19940304
DT Utility
FS GRANTED
EXNAM Primary Examiner: Coleman, Brenda
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 4088
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel pyrazolopyridine compound of the following formula: ##STR1##

wherein

R.sup.1 is aryl, and

R.sup.2 is cyclo(lower)alkyl which may have one or more suitable substituent(s), etc;

and a pharmaceutically acceptable salt thereof, which is useful as a medicament; the processes for the preparation of said pyrazolopyridine compound or a salt thereof; a pharmaceutical composition comprising said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof; etc.

L3 ANSWER 29 OF 36 USPATFULL on STN
AN 2001:10891 USPATFULL
TI Dihydropyrazine derivatives as NPY antagonists
IN Sit, Sing-Yuen, Meriden, CT, United States
Huang, Yazhong, West Haven, CT, United States
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI US 6177429 B1 20010123
AI US 2000-587817 20000606 (9)
PRAI US 1999-140343P 19990621 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Bernhardt, Emily
LREP Algieri, Aldo A.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 718
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a series of non-peptidergic antagonists of NPY comprising piperidine and piperazine derivatives of 4-phenyl-1,4-dihydropyrazines of the Formula I ##STR1##

wherein R, R.sup.1 X, Y and Z are defined herein. As antagonists of NPY-induced feeding behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating

disorders.

L3 ANSWER 30 OF 36 USPATFULL on STN
AN 2000:105920 USPATFULL
TI Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists
IN Cocuzza, Anthony J., Wilmington, DE, United States
Hobbs, Frank W., Wilmington, DE, United States
Beck, James P., Smyrna, DE, United States
Gilligan, Paul J., Wilmington, DE, United States
PA DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)
PI US 6103737 20000815
AI US 1998-109395 19980702 (9)
PRAI US 1997-51745P 19970703 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Howard C.; Assistant Examiner: White, Everett
LREP O'Brien, Maureen P., Rubin, Kenneth B.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1869
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Corticotropin releasing factor (CRF) antagonists of formula I: ##STR1## and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.

L3 ANSWER 31 OF 36 USPATFULL on STN
AN 2000:54132 USPATFULL
TI 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole derivatives of methylphenyl, methoxphenyl, and aminophenyl alkylsulfonamides and ureas and their use
IN Cournoyer, Richard Leo, San Francisco, CA, United States
Keitz, Paul Francis, Redwood City, CA, United States
O'Yang, Counde, Sunnyvale, CA, United States
Yasuda, Dennis Mitsugu, Campbell, CA, United States
PA F. Hoffman La Roche AG, Basel, Switzerland (non-U.S. corporation)
PI US 6057349 20000502
AI US 1999-264467 19990308 (9)
RLI Continuation of Ser. No. US 1998-89779, filed on 3 Jun 1998, now patented, Pat. No. US 5952362
PRAI US 1998-75978P 19980225 (60)
US 1997-50479P 19970623 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Geist, Gary; Assistant Examiner: Sackey, Ebenezer
LREP Clark, Janet Pauline, Kaku, Janet K.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4097
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns novel compounds represented by the Formula: ##STR1## wherein: A is R.sup.1.sub.q (R.sup.3 R.sup.60 N).sub.m (Z)(NR.sup.2).sub.n ; m and q are each 0 or 1, with the proviso that when q is 1, m is 0 and when q is 0, m is 1; Z is C.dbd.O or SO.sub.2 ; n is 1 with the proviso that, when Z is C.dbd.O, m is 1; X is --NH--,

--CH.sub.2 --, or --OCH.sub.2 --; Y is [2-imidazoline, 2-oxazolin] 2-thiazoline, [or 4-imidazole] R.sup.1 is H, lower alkyl, or phenyl, with the proviso that, when R.sup.1 is H, m is 1; R.sup.2, R.sup.3, R.sup.60 are each independently H, lower alkyl, or phenyl; R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are each independently hydrogen, lower alkyl, --CF.sub.3, lower alkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lower cycloalkyl, wherein R.sup.2 and R.sup.7 optionally may be taken together to form alkylene or alkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5- or 6-membered ring, wherein the optional substituents on the ring are halo, lower alkyl, or --CN, with the proviso that, when R.sup.7 is hydroxyl or lower alkylsulfonamido, then X is not --NH-- when Y is 2-imidazoline. The compounds include pharmaceutically acceptable salts of the above. In the above formula A may be, for example, (R.sup.1 SO.sub.2 NR.sup.2 --), (R.sup.3 R.sup.60 NSO.sub.2 NR.sup.2 --), or (R.sup.3 R.sup.60 NCONR.sup.2 --). The invention also includes the use of the above compounds, and compositions containing them, as alpha.sub.1A/1L agonists in the treatment of various disease states such as urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as **obesity**, bulimia, and anorexia.

L3 ANSWER 32 OF 36 USPATFULL on STN
AN 1999:110351 USPATFULL
TI 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole derivatives of methylphenyl, methoxyphenyl, and aminophenyl alkylsulfonamides and ureas and their use
IN Cournoyer, Richard Leo, San Francisco, CA, United States
Keitz, Paul Francis, Redwood City, CA, United States
O'Yang, Counde, Sunnyvale, CA, United States
Yasuda, Dennis Mitsugu, Campbell, CA, United States
PA Syntex (U.S.A) Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5952362 19990914
AI US 1998-89779 19980603 (9)
PRAI US 1998-75978P 19980225 (60)
US 1997-50479P 19970623 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Sackey, Ebenezer
LREP Clark, Janet Pauline, Kaku, Janet K.
CLMN Number of Claims: 85
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4539
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns novel compounds represented by the Formula: ##STR1## wherein: A is R.sup.1.sub.q (R.sup.3 R.sup.60 N).sub.m (Z)(NR.sup.2).sub.n ; m and q are each 0 or 1, with the proviso that when q is 1, m is 0 and when q is 0, m is 1; Z is C.dbd.O or SO.sub.2 ; n is 1 with the proviso that, when Z is C.dbd.O, m is 1; X is --NH--, --CH.sub.2 --, or --OCH.sub.2 --; Y is 2-imidazoline, 2-oxazoline, 2-thiazoline, or 4-imidazole; R.sup.1 is H, lower alkyl, or phenyl, with the proviso that, when R.sup.1 is H, m is 1; R.sup.2, R.sup.3, R.sup.60 are each independently H, lower alkyl, or phenyl; R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are each independently hydrogen, lower alkyl, --CF.sub.3, lower alkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lower cycloalkyl, wherein R.sup.2 and R.sup.7 optionally may be taken together to form alkylene or alkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5- or 6-membered ring, wherein the optional substituents on the ring are halo, lower alkyl, or --CN, with the proviso that, when R.sup.7 is hydroxyl or lower

alkylsulfonamido, then X is not --NH-- when Y is 2-imidazoline. The compounds include pharmaceutically acceptable salts of the above. In the above formula A may be, for example, (R.sup.1 SO.sub.2 NR.sup.2 --), (R.sup.3 R.sup.60 NSO.sub.2 NR.sup.2 --), or (R.sup.3 R.sup.60 NCONR.sup.2 --). The invention also includes the use of the above compounds, and compositions containing them, as alpha.sub.1A/1L agonists in the treatment of various disease states such as urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as **obesity**, bulimia, and anorexia.

L3 ANSWER 33 OF 36 USPATFULL on STN
AN 1999:40433 USPATFULL
TI Dihydropyrimidone derivatives as NPY antagonists
IN Bruce, Marc A., Wallingford, CT, United States
Poindexter, Graham S., Old Saybrook, CT, United States
Johnson, Graham, Madison, CT, United States
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI US 5889016 19990330
AI US 1998-9534 19980120
PRAI US 1997-50893P 19970626 (60)
US 1997-37183P 19970204 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Ford, John M.
LREP Algieri, Aldo A.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 717
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a series of non-peptidergic antagonists of NPY comprising piperidine derivatives of 4-phenyl-1,4-**dihydropyrimidinones** of the Formula I ##STR1## wherein R, R.sup.1 and R.sup.2 are defined herein. As antagonists of NPY-induced feeding behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.

L3 ANSWER 34 OF 36 USPATFULL on STN
AN 1998:75675 USPATFULL
TI Pyrazolopyridine adenosine antagonists
IN Akahane, Atsushi, Hyogo, Japan
Nishimura, Shintaro, Osaka, Japan
Itani, Hiromichi, Hyogo, Japan
Durkin, Kieran P. M., Folsom, CA, United States
PA Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)
PI US 5773530 19980630
WO 9518128 19950706
AI US 1996-663119 19960913 (8)
WO 1994-JP2230 19941226
19960913 PCT 371 date
19960913 PCT 102(e) date
PRAI GB 1993-26524 19931229
GB 1994-4323 19940304
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Coleman, Brenda
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1

DRWN No Drawings
LN.CNT 4147
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel pyrazolopyridine compound of the following formula: ##STR1## wherein R.sup.1 is aryl, and

R.sup.2 is cyclo(lower)alkyl which may have one or more suitable substituent(s), etc; and a pharmaceutically acceptable salt thereof, which is useful as a medicament; the processes for the preparation of said pyrazolopyridine compound or a salt thereof; a pharmaceutical composition comprising said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof; etc.

L3 ANSWER 35 OF 36 USPATFULL on STN
AN 92:84872 USPATFULL
TI Method of treatment using pyrazolopyridine compound
IN Shiokawa, Youichi, Ibaraki, Japan
Akahane, Atsushi, Kawabe, Japan
Katayama, Hirohito, Nishinomiya, Japan
Mitsunaga, Takafumi, Ashiya, Japan
PA Fujisawa Pharmaceutical Company, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 5155114 19921013
AI US 1991-715460 19910614 (7)
DCD 20080115
RLI Continuation-in-part of Ser. No. US 1990-626009, filed on 18 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-466929, filed on 12 Dec 1990, now patented, Pat. No. US 4985444, issued on 15 Jan 1991
PRAI GB 1989-1423 19890123
DT Utility
FS Granted
EXNAM Primary Examiner: Dentz, Bernard
LREP Oblon, Spivak, McClelland, Maier & Neustadt
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2525
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method for the prevention and/or treatment of renal toxicity, nephrosis or nephritis, which comprises administering a pyrazolopyridine compound of the formula: ##STR1## wherein R.sup.1 is aryl, and

R.sup.2 is unsaturated heterocyclic group which contains at least one heteroatom selected from the group consisting of N, O and S, which may have one or more suitable substituent(s), or a pharmaceutically acceptable salt thereof to a human being or an animal.

L3 ANSWER 36 OF 36 USPATFULL on STN
AN 91:5140 USPATFULL
TI Pyrazolopyridine compound and processes for preparation thereof
IN Shiokawa, Youichi, Ibaraki, Japan
Akahane, Atsushi, Hyogo, Japan
Katayama, Hirohito, Nishinomiya, Japan
Mitsunaga, Takafumi, Ashiya, Japan
PA Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)
PI US 4985444 19910115
AI US 1990-466929 19900118 (7)
PRAI GB 1989-1423 19890123
DT Utility
FS Granted

EXNAM Primary Examiner: Lee, Mary C.; Assistant Examiner: Dentz, Bernard I.
LREP Oblon, Spivak, McClelland, Maier & Neustadt
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2514
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to pyrazolopyridine compounds for the treatment of melancholia, heart failure, hypertension, renal insufficiency, edema, **obesity**, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, myocardiac infection, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack or angina pectoris, said compounds being of the formula ##STR1## wherein R.sup.1 is aryl, and

R.sup.2 is unsaturated heterocyclic group which contains at least one heteroatom selected from the group consisting of N, O and S, which may have one or more suitable substituent(s),

or a pharmaceutically acceptable salt thereof.

=> d his

(FILE 'HOME' ENTERED AT 12:12:40 ON 29 JUL 2003)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, NLDB, NUTRACEUT, ...' ENTERED AT 12:12:54 ON 29 JUL 2003

L1 51 S OBESITY AND DIHYDROPYRIMIDIN?
L2 5 S L1 AND PD<1999

FILE 'USPATFULL, ADISCTI, ADISINSIGHT, ADISNEWS, CEN, CFR, DIOGENES, DRUGNL, FEDREGFULL, IMSPROFILES, INVESTEXT, NLDB, NUTRACEUT, PHARMAML, PHIC, PHIN, PROMT, RDISCLOSURE, USPAT2' ENTERED AT 12:18:32 ON 29 JUL 2003

FILE 'USPATFULL' ENTERED AT 12:18:49 ON 29 JUL 2003
L3 36 S OBESITY AND DIHYDROPYRIMIDIN?

=> s l3 and pd<1999
2435652 PD<1999
(PD<19990000)
L4 3 L3 AND PD<1999

=> d l4 bib, ab, kwic

L4 ANSWER 1 OF 3 USPATFULL on STN
AN 1998:75675 USPATFULL
TI Pyrazolopyridine adenosine antagonists
IN Akahane, Atsushi, Hyogo, Japan
Nishimura, Shintaro, Osaka, Japan
Itani, Hiromichi, Hyogo, Japan
Durkin, Kieran P. M., Folsom, CA, United States
PA Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)
PI US 5773530 19980630 <--
WO 9518128 19950706 <--
AI US 1996-663119 19960913 (8)
WO 1994-JP2230 19941226
19960913 PCT 371 date
19960913 PCT 102(e) date

PRAI GB 1993-26524 19931229
GB 1994-4323 19940304
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Coleman, Brenda
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4147
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel pyrazolopyridine compound of the following formula: ##STR1## wherein R.sup.1 is aryl, and

R.sup.2 is cyclo(lower)alkyl which may have one or more suitable substituent(s), etc; and a pharmaceutically acceptable salt thereof, which is useful as a medicament; the processes for the preparation of said pyrazolopyridine compound or a salt thereof; a pharmaceutical composition comprising said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof; etc.

PI US 5773530 19980630 <--
WO 9518128 19950706 <--

SUMM . . . edema, nephrotic edema, hepatic edema, idiopathic edema, drug edema, acute angioneurotic edema, hereditary angioneurotic edema, carcinomatous ascites, gestational edema, etc); **obesity**, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer such as peptic ulcer (e.g. gastric ulcer, duodenal ulcer,. . .

SUMM . . . or more suitable substituent(s)" may include azepinyl (e.g. 1H-azepinyl, etc) pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl and its N-oxide, dihydropyridyl, pyrimidinyl, **dihydropyrimidinyl** (e.g. 1,2-**dihydropyrimidinyl**, etc), tetrahydropyrimidinyl (e.g. 1,2,3,4-tetrahydropyrimidinyl, etc), pyrazinyl, pyridazinyl, triazolyl (e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc), tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl) and the like;